Immediate Impact

8 from Science/Nature 64 standout
Sub-graph 1 of 23

Citing Papers

Metabolic reprogramming in the tumor microenvironment of liver cancer
2024 Standout
Natural killer cell therapies
2024 StandoutNature
1 intermediate paper

Works of Manik Amin being referenced

Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).
2021
Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).
2018

Author Peers

Author Last Decade Papers Cites
Manik Amin 343 160 62 123 53 566
Johannes Doescher 239 141 36 106 44 464
Annika Ålgars 383 118 28 146 34 635
Yu Fujiwara 280 64 39 90 53 481
Charlene Mantia 262 122 75 122 50 608
Maarit Ahtiainen 340 76 39 162 43 592
Seisho Sakai 185 102 64 135 44 544
Ken Kojo 161 122 61 200 28 468
Dariusz Waniczek 243 109 62 206 56 568
Nagla Abdel Karim 269 83 172 185 60 599
Feng Wang 230 94 68 262 51 572

All Works

Loading papers...

Rankless by CCL
2026